AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22627182 — intervention group
Group type: COMPARATOR
Intervention: Comparison of pitavastatin with and without lopinavir/ritonavir
Number of subjects: 24
Study 22627615 — intervention group
Group type: EXPERIMENTAL
Intervention: Reader interpretation of chest radiographs (CXRs) for NCNs
Number of subjects: 100
Study 22627615 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up recommendations based on CXR interpretation
Number of subjects: 100
Study 22627678 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin 50-mg twice-daily dose schedule
Number of subjects: 0
Study 22627678 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin 100-mg twice-daily dose schedule
Number of subjects: 0
Study 22627678 — intervention group
Group type: EXPERIMENTAL
Intervention: Midostaurin in combination with standard chemotherapy
Number of subjects: 0
Study 22631877 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Centred Rehabilitation Model (PCRM-CI)
Number of subjects: 70
Study 22631877 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study 22633255 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ovulation induction with clomiphene citrate followed by exogenous gonadotropins
Number of subjects: 108
Study 22633255 — intervention group
Group type: EXPERIMENTAL
Intervention: First model (age, duration of infertility, insulin/glucose ratio)
Number of subjects: 108
Study 22633255 — intervention group
Group type: EXPERIMENTAL
Intervention: Second model (age, duration of infertility, body mass index)
Number of subjects: 108
Study 22633255 — intervention group
Group type: EXPERIMENTAL
Intervention: First model
Number of subjects: 108
Study 22633255 — intervention group
Group type: EXPERIMENTAL
Intervention: Second model
Number of subjects: 108
Study 22633265 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonists with serum P levels ≥ 2.0 ng/mL
Number of subjects: 2555
Study 22633265 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonists with serum P levels <1.5 ng/mL
Number of subjects: 2555
Study 22633265 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonists with serum P levels 1.5-1.99 ng/mL
Number of subjects: 2555
Study 22633265 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonists
Number of subjects: 2555
Study 22633322 — intervention group
Group type: EXPERIMENTAL
Intervention: Na-ASP-2 vaccine
Number of subjects: 0
Study 22633322 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine
Number of subjects: 0
Study 22633346 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial transfer (DMET) for Fuchs endothelial dystrophy
Number of subjects: 12
Study 22633346 — intervention group
Group type: EXPERIMENTAL
Intervention: Descemet membrane endothelial transfer (DMET) for bullous keratopathy
Number of subjects: 12
Study 22633629 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive topiramate
Number of subjects: 284
Study 22633670 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline plasma cardiac troponin I levels
Number of subjects: 49
Study 22633670 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and disease onset
Number of subjects: 49
Study 22633670 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiogram parameters
Number of subjects: 49
Study 22633670 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline electrocardiograms
Number of subjects: 49
Study 22634397 — intervention group
Group type: EXPERIMENTAL
Intervention: Iniparib plus paclitaxel and carboplatin
Number of subjects: 17
Study 22634397 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study 22634437 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 vaccine 160U (only for children)
Number of subjects: 100
Study 22634437 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 vaccine 320U
Number of subjects: 100
Study 22634437 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 vaccine 640U
Number of subjects: 100
Study 22634437 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 vaccine (all doses)
Number of subjects: 100
Study 22634437 — intervention group
Group type: EXPERIMENTAL
Intervention: EV71 vaccine (one dose)
Number of subjects: 100
Study 22634621 — intervention group
Group type: EXPERIMENTAL
Intervention: AAT-treated stimulated DC (0.5 mg/ml human AAT)
Number of subjects: 0
Study 22634621 — intervention group
Group type: EXPERIMENTAL
Intervention: AAT treatment (60 mg/kg)
Number of subjects: 0
Study 22634621 — intervention group
Group type: EXPERIMENTAL
Intervention: AAT-treated cells
Number of subjects: 0
Study 22634621 — intervention group
Group type: EXPERIMENTAL
Intervention: AAT-treated DC
Number of subjects: 0
Study 22638007 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT) for depression
Number of subjects: 135
Study 22638007 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 135
Study 22639293 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid infusion (20% Intralipid at 90 ml/h)
Number of subjects: 28
Study 22639293 — intervention group
Group type: COMPARATOR
Intervention: Glycerol infusion (2.25 g/100 ml at 90 ml/h)
Number of subjects: 28
Study 22639402 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissociative subtype of PTSD (high PTSD severity with high levels of dissociation)
Number of subjects: 644
Study 22640652 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal flu vaccine (SFV) - 1 dose, Mutagrip®
Number of subjects: 199
Study 22640652 — intervention group
Group type: EXPERIMENTAL
Intervention: A/H1N1 flu vaccine (HFV) - 2 doses at a 3-week interval, Panenza®
Number of subjects: 199
Study 22640652 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines (SFV and HFV)
Number of subjects: 199
Study 22642956 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-channel mucosal impedance (MI) catheter measurements at the site of erosive mucosa
Number of subjects: 69
Study 22642956 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-channel mucosal impedance (MI) catheter measurements at 2 cm above the squamocolumnar junction in patients with GERD
Number of subjects: 69
Study 22642956 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-channel mucosal impedance (MI) catheter measurements along the esophagus in patients with GERD
Number of subjects: 69
Study 22643560 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (15 mg/kg every 3 weeks) and Erlotinib (150 mg daily)
Number of subjects: 21
Study 22643560 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Erlotinib
Number of subjects: 21
Study 22643560 — intervention group
Group type: COMPARATOR
Intervention: Placebo (historical control from Sorafenib trial)
Number of subjects: 21
Study 22644887 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) and near-infrared spectroscopy (NIRS) monitoring during liver transplantation
Number of subjects: 9
Study 22644887 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD) and near-infrared spectroscopy (NIRS) monitoring
Number of subjects: 9
Study 22644957 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocytoscopy (EC) with methylene blue or toluidine blue application
Number of subjects: 40
Study 22645182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib (first-line therapy)
Number of subjects: 0
Study 22646832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral leg (Villalta score)
Number of subjects: 367
Study 22646832 — intervention group
Group type: COMPARATOR
Intervention: Contralateral leg (Villalta score)
Number of subjects: 367
Study 22646832 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsilateral PTS (defined by Villalta score >4)
Number of subjects: 367
Study 22646832 — intervention group
Group type: COMPARATOR
Intervention: Contralateral leg (Villalta score >4)
Number of subjects: 367
Study 22646832 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Villalta scores
Number of subjects: 367
Study 22647431 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept therapy (anti-TNF) for 12 weeks
Number of subjects: 97
Study 22647519 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous IV infusion of adenosine via the forearm vein (140 μg/min/kg)
Number of subjects: 71
Study 22647519 — intervention group
Group type: COMPARATOR
Intervention: Continuous IV infusion of adenosine via the femoral vein (140 μg/min/kg)
Number of subjects: 71
Study 22647519 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary bolus injection of adenosine
Number of subjects: 71
Study 22647519 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional bolus injection of adenosine during IV infusion
Number of subjects: 71
Study 22647519 — intervention group
Group type: COMPARATOR
Intervention: Both routes of adenosine infusion (femoral vs. forearm)
Number of subjects: 71
Study 22647519 — intervention group
Group type: COMPARATOR
Intervention: Hyperemic mean transit time and index of microcirculatory resistance
Number of subjects: 71
Study 22647561 — intervention group
Group type: EXPERIMENTAL
Intervention: VolumeView/EV1000™ system
Number of subjects: 72
Study 22647561 — intervention group
Group type: COMPARATOR
Intervention: PiCCO™ method
Number of subjects: 72
Study 22648179 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dosing of trastuzumab emtansine (T-DM1) at 2.4 mg/kg
Number of subjects: 28
Study 22648179 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly dosing of trastuzumab emtansine (T-DM1)
Number of subjects: 28
Study 22648486 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial limited compression ultrasonography (CUS)
Number of subjects: 0
Study 22648486 — intervention group
Group type: EXPERIMENTAL
Intervention: Single complete compression ultrasonography (CUS)
Number of subjects: 0
Study 22649106 — intervention group
Group type: EXPERIMENTAL
Intervention: GATA2 zinc finger 1 mutations in biCEBPA-positive CN-AML patients
Number of subjects: 33
Study 22649106 — intervention group
Group type: COMPARATOR
Intervention: GATA2 mutations presence
Number of subjects: 33
Study 22649106 — intervention group
Group type: EXPERIMENTAL
Intervention: GATA2 mutations (n=10)
Number of subjects: 33
Study 22649106 — intervention group
Group type: EXPERIMENTAL
Intervention: GATA2 ZF1 mutants in reporter gene assays
Number of subjects: 33
Study 22649108 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional flow cytometry (MDF) for detecting residual disease (RD)
Number of subjects: 249
Study 22649177 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused sonographic examination of the heart, lungs and deep veins
Number of subjects: 0
Study 22649177 — intervention group
Group type: COMPARATOR
Intervention: Usual diagnostic work up
Number of subjects: 0
Study 22651703 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib alone
Number of subjects: 20
Study 22651703 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib and GDC-0973 combination
Number of subjects: 20
Study 22651703 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib in mice with drug-resistant A375 xenografts
Number of subjects: 20
Study 22651703 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib and GDC-0973 combination efficacy
Number of subjects: 20
Study 22651868 — intervention group
Group type: EXPERIMENTAL
Intervention: LNA-34a (locked nucleic acid modified inhibitor)
Number of subjects: 49
Study 22651868 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of miR-34a
Number of subjects: 49
Study 22651868 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment of BMCs with LNA-34a ex vivo
Number of subjects: 49
Study 22651868 — intervention group
Group type: COMPARATOR
Intervention: BMCs from patients with myocardial infarction
Number of subjects: 49
Study 22652031 — intervention group
Group type: EXPERIMENTAL
Intervention: EBUS-TBNA
Number of subjects: 77
Study 22652031 — intervention group
Group type: COMPARATOR
Intervention: Mediastinoscopy
Number of subjects: 77
Study 22652104 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal external beam accelerated partial breast irradiation (3D-APBI) at 32 Gy delivered in 8 twice-daily fractions
Number of subjects: 98
Study 22652104 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-APBI
Number of subjects: 98
Study 22653976 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib combined with vincristine, dexamethasone, pegylated asparaginase, and doxorubicin
Number of subjects: 22
Study 22653976 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib combined with chemotherapy
Number of subjects: 22
Study 22653976 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib combined with chemotherapy and prophylactic antibiotics (vancomycin, levofloxacin, voriconazole)
Number of subjects: 22
Study 22655593 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated cell biodelivery (ECB) implants delivering nerve growth factor (NGF)
Number of subjects: 6
Study 22656234 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (750 mg/m(2) on days 1, 8, 15, and 22) and Temozolomide (150 mg/m(2) days 1-7 and 15-21) followed by consolidation Temozolomide (150-200 mg/m(2) × 5/28 days) and maintenance with Methylprednisolone (1 g IV every 28 days) until progression
Number of subjects: 16
Study 22658254 — intervention group
Group type: EXPERIMENTAL
Intervention: Early abciximab administration before primary PCI
Number of subjects: 262
Study 22658254 — intervention group
Group type: COMPARATOR
Intervention: Late abciximab administration before primary PCI
Number of subjects: 262
Study 22659939 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2peak >27.3 ml/kg/min
Number of subjects: 51
Study 22659939 — intervention group
Group type: COMPARATOR
Intervention: VO2peak ≤27.3 ml/kg/min
Number of subjects: 51
Study 22659961 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood-smoke exposure (WSE)
Number of subjects: 914
Study 22659961 — intervention group
Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 914
Study 22660962 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression ultrasound of a forearm vein (CUS)
Number of subjects: 81
Study 22660962 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior vena cava collapsibility (IVC-C)
Number of subjects: 81
Study 22660962 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal jugular vein collapsibility (IJV-C)
Number of subjects: 81
Study 22661451 — intervention group
Group type: EXPERIMENTAL
Intervention: PCWP 16 to 18 mm Hg
Number of subjects: 268
Study 22661451 — intervention group
Group type: COMPARATOR
Intervention: PCWP ≤ 15 mm Hg
Number of subjects: 268
Study 22661451 — intervention group
Group type: EXPERIMENTAL
Intervention: PCWP increased to 19 mm Hg
Number of subjects: 268
Study 22661451 — intervention group
Group type: COMPARATOR
Intervention: PCWP ≤ 18 mm Hg
Number of subjects: 268
Study 22661451 — intervention group
Group type: EXPERIMENTAL
Intervention: All PCWP subgroups
Number of subjects: 268
Study 22661464 — intervention group
Group type: EXPERIMENTAL
Intervention: Argus II retinal prosthesis
Number of subjects: 21
Study 22661474 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (monthly intravitreal injections)
Number of subjects: 0
Study 22661483 — intervention group
Group type: EXPERIMENTAL
Intervention: Inner zone atrophy
Number of subjects: 413
Study 22661483 — intervention group
Group type: COMPARATOR
Intervention: Outer zone atrophy
Number of subjects: 413
Study 22661483 — intervention group
Group type: COMPARATOR
Intervention: Superior outer subfield atrophy
Number of subjects: 413
Study 22661748 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired autoregulation during CPB (Mx ≥0.40)
Number of subjects: 234
Study 22661748 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired autoregulation (Mx ≥0.40)
Number of subjects: 234
Study 22661748 — intervention group
Group type: COMPARATOR
Intervention: Preserved autoregulation (Mx <0.40)
Number of subjects: 234
Study 22662137 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing antibodies against EV71 in infants at 2 months
Number of subjects: 975
Study 22662137 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal antibody titers
Number of subjects: 975
Study 22662137 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulate incidence density of HFMD
Number of subjects: 975
Study 22662137 — intervention group
Group type: EXPERIMENTAL
Intervention: Seropositivity of EV71 antibody in infants
Number of subjects: 975
Study 22664059 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavopiridol (100 mg/m2 IV, 24 h infusion) and Cisplatin (60 mg/m2 IV)
Number of subjects: 45
Study 22664410 — intervention group
Group type: EXPERIMENTAL
Intervention: Taking Action Together (TAT) intervention
Number of subjects: 0
Study 22664410 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 22665938 — intervention group
Group type: EXPERIMENTAL
Intervention: CRd (carfilzomib 36 mg/m2, lenalidomide 25 mg/d, dexamethasone 40/20 mg)
Number of subjects: 53
Study 22666789 — intervention group
Group type: EXPERIMENTAL
Intervention: Case arm (urolithiasis)
Number of subjects: 51
Study 22668067 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg (single dose on day 1 and once daily on days 3-7)
Number of subjects: 16
Study 22668067 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg (single dose and once-daily doses for 5 days)
Number of subjects: 16
Study 22670903 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib (150 mg oral daily)
Number of subjects: 96
Study 22673018 — intervention group
Group type: EXPERIMENTAL
Intervention: Light activity
Number of subjects: 102
Study 22673018 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 102
Study 22673018 — intervention group
Group type: EXPERIMENTAL
Intervention: MVPA accumulated in bouts
Number of subjects: 102
Study 22673018 — intervention group
Group type: COMPARATOR
Intervention: Activity variables
Number of subjects: 102
Study 22674435 — intervention group
Group type: EXPERIMENTAL
Intervention: L19-TNF ILP at 325 µg
Number of subjects: 17
Study 22674435 — intervention group
Group type: EXPERIMENTAL
Intervention: L19-TNF ILP at 650 µg
Number of subjects: 17
Study 22674435 — intervention group
Group type: COMPARATOR
Intervention: Standard melphalan-containing ILP
Number of subjects: 17
Study 22676070 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2 to 6 mg/day) for 6 months
Number of subjects: 390
Study 22676070 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2 to 6 mg/day) for 12 months
Number of subjects: 390
Study 22676070 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (2 to 6 mg/day)
Number of subjects: 390
Study 22676070 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone maintenance treatment
Number of subjects: 390
Study 22676992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine fetal death (IUFD)
Number of subjects: 368
Study 22677155 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (20 mg) plus rituximab
Number of subjects: 52
Study 22677240 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) in the Geriatric Department (GD)
Number of subjects: 3877
Study 22677240 — intervention group
Group type: COMPARATOR
Intervention: General medical care in the Medical Department (MD)
Number of subjects: 3877
Study 22677278 — intervention group
Group type: EXPERIMENTAL
Intervention: Beat Averaging (BA) using one beat
Number of subjects: 173
Study 22677278 — intervention group
Group type: EXPERIMENTAL
Intervention: Beat Averaging (BA) using two beats
Number of subjects: 173
Study 22677278 — intervention group
Group type: EXPERIMENTAL
Intervention: Beat Averaging (BA) using three beats
Number of subjects: 173
Study 22677278 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable type (slopes and calculated variables)
Number of subjects: 173
Study 22677278 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable type (chamber dimensions, areas, velocities, and time intervals)
Number of subjects: 173
Study 22677455 — intervention group
Group type: EXPERIMENTAL
Intervention: Concordant LV leads
Number of subjects: 103
Study 22677455 — intervention group
Group type: COMPARATOR
Intervention: Discordant LV leads
Number of subjects: 103
Study 22677455 — intervention group
Group type: COMPARATOR
Intervention: Discordant LV leads (+1 segment)
Number of subjects: 103
Study 22677455 — intervention group
Group type: COMPARATOR
Intervention: Discordant LV leads (+2 segments)
Number of subjects: 103
Study 22681857 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status measured using a visual analogue scale (VAS)
Number of subjects: 150
Study 22681857 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting List Impact Questionnaire (WLIQ)
Number of subjects: 150
Study 22681857 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent predictors of lower VAS scores
Number of subjects: 150
Study 22681919 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg dose)
Number of subjects: 59
Study 22682017 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-1R monoclonal antibody therapy (R1507, IMC-A12, SCH 717454, CP-751.871)
Number of subjects: 12
Study 22682069 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical intervention (surgery within 6 months of birth)
Number of subjects: 0
Study 22682069 — intervention group
Group type: COMPARATOR
Intervention: Late surgical intervention (surgery after 6 months of birth)
Number of subjects: 0
Study 22682069 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis obtained in utero
Number of subjects: 0
Study 22682069 — intervention group
Group type: COMPARATOR
Intervention: Diagnosis obtained at birth
Number of subjects: 0
Study 22682146 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (Norditropin®)
Number of subjects: 120
Study 22682691 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent, personalized, paper-based educational messages and reminders sent via post.
Number of subjects: 0
Study 22684655 — intervention group
Group type: COMPARATOR
Intervention: 3rd SUA tertile
Number of subjects: 100
Study 22684655 — intervention group
Group type: EXPERIMENTAL
Intervention: SUA
Number of subjects: 100
Study 22684655 — intervention group
Group type: EXPERIMENTAL
Intervention: serum creatinine
Number of subjects: 100
Study 22684655 — intervention group
Group type: EXPERIMENTAL
Intervention: sTNF-alpha
Number of subjects: 100
Study 22685032 — intervention group
Group type: EXPERIMENTAL
Intervention: TLR3-ligand polyinosinic: polycytidylic acid (poly(I:C))
Number of subjects: 133
Study 22685032 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic epithelial cell lines HT-29 and SW620
Number of subjects: 133